by alexcastillo | Nov 11, 2020 | MAT Resources
Recommendations from the NM Medical Advisory Team include, but are not limited to: 1. Bamlanivimab should be distributed to centers with the capacity for intravenous administration and monitoring of outpatients who meet criteria of administration under the FDA...
by alexcastillo | Nov 9, 2020 | MAT Resources
In August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for the treatment of hospitalized patients with COVID-19.The use of COVID-19 Convalescent Plasma (CCP) collected from individuals who...
by alexcastillo | Oct 27, 2020 | MAT Resources
Remdesivir, under the trade name VEKLURY, should be used according to the prescribing guidelines provided in the FDA approval issued 10/2020.1 The drug is intended for use in patients 12 years of age and older and weighing at least 40 kg for the treatment of...
by alexcastillo | Oct 6, 2020 | MAT Resources
Rapid antigen tests have recently emerged and offer significant improvement for near patient turn-around-time. Rapid antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) that meet the requirements to...
by alexcastillo | Sep 14, 2020 | MAT Resources
This document outlines a series of responses to COVID-19 frequently asked questions, including information about finding New Mexico COVID-19 cases by county, risk of transmission in certain settings (e.g. dining, gyms), and COVID-19 deaths. Download this...
by alexcastillo | Sep 3, 2020 | MAT Resources
The Mat defines predicted increases in need for behavioral health services during and after the pandemic; defines existing capacity and needed expansion of that capacity; and, outlines needed capacity expansion in an actionable format. Download this...
